ECE2010 Poster Presentations Obesity (50 abstracts)
The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the metabolic syndrome components and body composition
Yuliya Tishova 1 , Svetlana Kalinchenko 1 , George Mskhalaya 1 , Farid Saad 2, , Louis J G Gooren 4 & Erik J Giltay 1
1Chair of Endocrinology, People’s Friendship University of Russia, Moscow, Russian Federation; 2Bayer Schering Pharma, Scientific Affairs Men’s Healthcare, Berlin, Germany; 3Gulf Medical University School of Medicine, Ajman, UAE; 4Department of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands; 5Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands.
Background: Metabolic syndrome has a high prevalence in male population, leading to the high rate of cardiovascular disease and mortality. Numerous studies show that low androgen levels in men are associated with the metabolic syndrome. This study tested whether normalization of testosterone levels improves metabolic dysregulations and body composition.
Methods: In a randomized, placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identifier: NCT00696748), 184 men suffering from both the metabolic syndrome and hypogonadism (total testosterone level <12 nmol/l) were included. They were treated for 30 weeks with either parenteral testosterone undecanoate (TU; 1000 mg testosterone undecanoate at baseline, and after 6 and 18 weeks; Nebido) or placebo. 105 (92.9%) men receiving TU and 65 (91.5%) receiving placebo completed the trial.
Results: The 184 men were aged between 35 and 70 years old, with a mean age of 51.6 (95% confidence interval (CI): 49.8–53.4) in the TU group and 52.8 (95% CI: 50.5–55.0) in the placebo group. In the Nebido group, there were significant improvements in weight, body mass index, waist circumference and waist-to-hip ratio (P<0.001). Levels of leptin (P=0.001) and insulin (P=0.04) decreased. There were no changes in glucose and lipids, although there was a statistical trend for a reduction in LDL cholesterol (P=0.07).
Conclusions: Thirty weeks of TU administration strongly improved anthropometric parameters as compared to placebo.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more